CytomX Therapeutics (CTMX) Gets a Buy Rating from Mizuho Securities


In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on CytomX Therapeutics (CTMX), with a price target of $16.00. The company’s shares closed last Monday at $7.13.

According to TipRanks.com, Goldstein is a 3-star analyst with an average return of 1.4% and a 35.6% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Fate Therapeutics, and Arcus Biosciences.

Currently, the analyst consensus on CytomX Therapeutics is a Strong Buy with an average price target of $15.67, implying a 122.6% upside from current levels. In a report issued on February 24, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.63 and a one-year low of $5.10. Currently, CytomX Therapeutics has an average volume of 395K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts